FDA
-
-
-
-
-
-
-
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the Year
-
-
-
-
-
-
-
Kamada declares $0.25 per share cash dividend under new annual policy
-
-
-
-
-
-
-
Kamada discontinues Phase 3 inhaled AAT trial after futility analysis
-
-
-
-
-
-
-
Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance
-
-
-
-
-
-
-
Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®
-
-
-
-
-
-
-
How Kamada (NASDAQ: KMDA) Is Transforming Its Strategic Focus Into Commercial Growth
-
-
-
-
-
-
-
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024
-
326,003 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

